Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
about
sameAs
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuApoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2The physiological action of picolinic Acid in the human brainThe role of vascular cell adhesion molecule-1 in tumor immune evasionAdoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cellsOn evolutionary origin of cancerT cell avidity and tumor recognition: implications and therapeutic strategies.Clinical significance of T cell metabolic reprogramming in cancerImmune Mechanisms in Myelodysplastic SyndromeUntil Death Do Us Part: Necrosis and Oxidation Promote the Tumor MicroenvironmentMesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Metabolic communication in tumors: a new layer of immunoregulation for immune evasionEndotoxin-Induced Tryptophan Degradation along the Kynurenine Pathway: The Role of Indolamine 2,3-Dioxygenase and Aryl Hydrocarbon Receptor-Mediated Immunosuppressive Effects in Endotoxin Tolerance and Cancer and Its Implications for ImmunoparalysisT Cells and Cancer: How Metabolism Shapes ImmunityAdvances in immunotherapy for melanomaNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Understanding the role of the kynurenine pathway in human breast cancer immunobiologyTargeting amino acid metabolism in cancer growth and anti-tumor immune responseTargeting the indoleamine 2,3-dioxygenase pathway in cancerRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsThe Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and AutoimmunityImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesT cell metabolism drives immunityHost-pathogen interactions between the human innate immune system and Candida albicans-understanding and modeling defense and evasion strategiesImplication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allograftsThe role of IDO in brain tumor immunotherapyLung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionTumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsRole of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune responseMyeloid-derived suppressor cells and anti-tumor T cells: a complex relationshipImpaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Novel immunotherapies for hematologic malignanciesTrial watch: IDO inhibitors in cancer therapyThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentMolecular pathways: not a simple tube--the many functions of blood vesselsIndoleamine 2,3 dioxygenase in intestinal diseaseCancer immunotherapyMolecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase
P2860
Q21131200-1FCCBAAB-E995-4795-ACD7-DE29C98A64C0Q21245649-FB190BE4-ECDA-4478-B960-DFCE0C8295CAQ24634995-281B982E-775C-4155-93C7-C2EEEC6BCB92Q24635847-6FCD56D3-B132-4298-B91C-C9545CB85D29Q24802970-9E68DB86-7AD2-4E0A-A27B-B62195C66809Q24803579-AA00AA8E-3F65-465E-9C43-1DDB63C98299Q24815775-5E0FB372-96B4-42E2-A9C6-604EAD33EA28Q26741974-2835D3EB-5DC8-4AF0-AAB8-E2AC1936D347Q26744500-99119487-4480-428D-8A1E-118F0EADA6C2Q26745898-760D3C44-A0E2-4867-8770-ECA662994CDBQ26746104-F22D369E-41EF-425E-8FBB-015D5797C9EFQ26765256-8BB0E193-AE40-4B77-82AD-096FAE6E3297Q26765777-B6183E64-A102-44F0-8495-7694946139A4Q26766427-6C90D1D6-7680-4FDF-B68B-25533B4C5926Q26768558-B6D81BCD-B045-4572-B1AE-247792017D93Q26769884-2D125178-951C-49D6-B1F9-D33D59D075E3Q26770391-451D46E4-2633-4D8A-B837-C8744C60B6FBQ26773472-6FD73CCE-288E-4224-8E53-2524A88CA646Q26775425-AC6A2171-CD23-4EBD-8EE6-BFFAC7A9EB36Q26775471-FFF3447A-4885-4E44-8397-A6573056CEEEQ26779221-E4F0B0D1-F8C5-4658-BDD1-00B3256BE958Q26785900-B21564B8-6383-43A4-AAC5-75CBD1CC511EQ26798402-EAF52354-0692-43E2-AA55-3FDA11CA37ACQ26799575-FA25D7A9-A5C7-4C7C-82B7-63E751155CAEQ26801655-A474AB09-0E5C-4DD0-BB15-5AF15FCB9860Q26825202-698BD426-768C-4BC2-8FCE-44ECD70ED51AQ26830399-EF1E3906-D487-4881-8DF4-029CA7774533Q26850218-DEE26673-E1BF-4969-BB51-431B3FE5595EQ26862220-2FA5EAF8-E0F4-4A81-8E2B-CDF13DD3F686Q26865532-CC39A3DA-95BC-4581-9BA1-C91E68C0DFD2Q26996330-D49AE461-D67E-44ED-812B-A62A8D44F947Q27000087-EF567E4A-A92B-4A38-9421-91D83F99A464Q27003955-F6EE1603-A1B1-4D7C-AE02-BC21254C4FA2Q27004436-1A95E801-E4C3-444F-AA03-31AC0DE0D42EQ27006866-2E4256A5-CE07-4FA2-8E77-08F4DC14BFDCQ27022789-32E80F17-EBB4-4F3F-B449-D78CF1E46BEFQ27025036-4A474A20-9AB0-42AC-A73B-FD5F7FD08B34Q27025063-BEBCF38E-BF7D-4F12-B0C5-8A9A56181F08Q27026870-F00D62FC-2A0F-47CB-8288-60DDD6FC5B6AQ27641013-62CE2DAA-BB39-4D96-A91E-76554CDF7735
P2860
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@ast
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@en
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@nl
type
label
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@ast
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@en
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@nl
prefLabel
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@ast
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@en
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@nl
P2093
P3181
P356
P1433
P1476
Evidence for a tumoral immune ...... by indoleamine 2,3-dioxygenase
@en
P2093
Benoît J Van den Eynde
Catherine Uyttenhove
Didier Colau
Ivan Théate
Luc Pilotte
Nicolas Parmentier
Thierry Boon
Vincent Stroobant
P2888
P304
P3181
P356
10.1038/NM934
P407
P577
2003-10-01T00:00:00Z